TP53 and cancer: Eligible patients will be assigned to one of the four RAINBOW trials (ClinicalTrials.gov Identifier: NCT05255653) based on the molecular profile of their cancers: p53 abnormal EC patients to the p53abn-RED trial; MSI-h/dMMR EC patients to the MMRd-GREEN trial; no specific molecular profile EC patients to NSMP-ORANGE trial and POLE mutant EC patients to the POLEmut-BLUE trial.